Peppermint VenturePartners

PVP’s pipeline is built on formal partnerships with Charité – Universitätsmedizin Berlin and the Helmholtz Association. The firm’s CBF 1 fund uses the Charité network to translate medical research into startups, while its sister company PVP Advisors externally manages the Helmholtz Validation Fund, which screens projects across 18 national labs with an annual budget exceeding €5 billion. PVP partners also serve as judges and mentors in EIT Health and EIC Accelerator programs.

PVP operates as an independent venture capital firm. It grew out of Peppermint Holding, the industrial group founded by Ingeborg Neumann, but relaunched in 2010 as a standalone fund manager raising institutional and entrepreneurial capital. It is not structured as a single family office.

PVP focuses on early-stage companies, typically from pre-seed through expansion. CBF 1 targets early-stage interventions in MedTech, Digital Health, and pharma platforms. The planned LIIDO fund will shift slightly later, targeting technology-driven life science tools and services companies that have achieved market traction and initial revenues.

PVP invests directly into portfolio companies from its own fund vehicles. The firm does not act as a fund-of-funds manager. Co-investment is a central feature: CBF 1 portfolio companies have attracted €185 million from global co-investors alongside PVP’s initial capital.

Peppermint Holding is the mid-sized industrial group founded by Ingeborg Neumann in 1997, active in high-end textiles. The first venture capital fund was launched within the holding in 2000. In 2010, Peppermint VenturePartners was relaunched as a separate, independent fund management entity, though Neumann remains the common principal across both entities.

LIIDO — Laboratory Intelligence Innovations Digitalization and Operations — is a planned €100 million fund that PVP aims to launch in 2025. It will focus on life science tools and services companies in Europe, prioritizing DACH, the UK, and Scandinavia. The strategy emphasizes providing go-to-market expertise to portfolio companies with existing revenue traction.

Investment decisions are led by the three managing partners: Ingeborg Neumann, Dr. Joachim Rautter, and Dr. Klaus Stöckemann. Neumann provides the entrepreneurial and holding-company oversight; Rautter chairs several portfolio company boards and led earlier PVP investment activities; Stöckemann brings 20 years of venture experience, including a prior role as general partner in 3i’s international healthcare team.